Tagged with IT

Switzerland Juergen Nelis, CEO of BGG World Holding, discusses the company’s strategic growth and evolving approach to sustainability, market expansion, and product innovation. He highlights key initiatives such as expanding production capabilities outside of China and refining BGG’s global leadership structure, while also addressing the challenges posed by geopolitical factors and…

Saudi Arabia With increased average disposable income in Saudi Arabia eliciting more sedentary lifestyles and less healthy dietary choices, more than 68 percent of all mortality in the Kingdom is nowadays attributed to non-communicable diseases (NCDs). Not only does this come at immense cost to the public purse, but also presents a…

Global Radioligand therapy (RLT), a specialized type of radiopharmaceutical therapy (RPT) that targets markers on tumor cells, is becoming a cancer treatment game changer. With a first FDA approval for Novartis’ Pluvicto, RLT has proved its potential. But are current regulatory frameworks and healthcare systems prepared to integrate this less-than-typical therapy?…

Investment In a year marked by uncertainty and tighter capital flows, the competition to attract life sciences investment has never been fiercer. Global hubs are not just showcasing infrastructure or talent – they’re fighting for the soul, and pockets, of the industry’s future. We spoke to the CEOs of regional investment…

Switzerland Combining scientific rigour with entrepreneurial instinct, Igor Fisch charts a new path for gene and cell therapy manufacturing at NewBiologix. Focused on addressing the inefficiencies of current production models, the company develops stable platforms designed to lower costs, enhance quality, and expand patient access. With roots in the pioneering success…

Switzerland Daniela Marino, CEO and co-founder of CUTISS, leads a pioneering Swiss “tech-bio” company developing personalised skin grafts through advanced tissue engineering. With roots in academic research and over EUR 90 million raised, CUTISS has brought its lead product into Phase III trials, targeting burns and reconstructive surgery. Their unique approach…

Switzerland Catherine Pickering, CEO of iOnctura, explains how her agile Swiss biotech is pioneering precision small-molecule therapies to overcome tumour resistance, with a focus on lead asset – roginolisib and a pipeline built on novel scientific mechanisms. She discusses the company’s evolution from seed funding through Series B and the role…

Switzerland Mads Stoustrup, co-founder and CEO of Azento Health, shares his journey from 22 years at Novo Nordisk to launching a science-driven startup focused on supporting patients undergoing GLP-1 treatment for obesity. Azento Health develops clinically backed probiotic supplements, designed to reduce gastrointestinal side effects and improve treatment adherence. Backed by…

Switzerland The transformation of CEVA Logistics’ healthcare strategy – led by industry veteran Eric ten Kate – is unfolding with quiet precision and sharp focus. As part of the CMA CGM Group and with a mandate rooted in operational excellence, digital intelligence, and regional depth, CEVA is redefining its position in…

Switzerland Michele Ravara brings a global perspective and deep strategic experience to his role as general manager of AbbVie Switzerland, following nearly a decade leading the Oncology Business from a global standpoint in the US. In just over two months, he has embraced Switzerland’s complex healthcare ecosystem and diverse talent landscape,…

Italy Banking on three key therapeutic areas, including a newly established rare disease franchise, the Italian midcap Chiesi has pursued a sweeping transformation in recent years. In its reboot efforts, the company has not only made significant R&D investments, but pursued key M&A and partnership deals, and aimed for global expansion.…

Switzerland Founded in 2017 by a group of biotech veterans with deep expertise in antibody engineering, CDR-Life has evolved into a platform-driven company advancing next-generation T-cell engagers for oncology and autoimmune disease. With assets progressing through clinical trials and a strategic partnership already in place, CEO Christian Leisner discusses how the…